Effectiveness of Monthly Low Dose Emicizumab Prophylaxis Without 4-week Loading Doses Among Patients with Haemophilia A with and Without Inhibitors: A Case Series Report
Overview
Authors
Affiliations
Mao Q, Chen Z, Liu G, Li G, Zhen Y, Cheng X Pediatr Investig. 2024; 8(4):244-252.
PMID: 39720280 PMC: 11664537. DOI: 10.1002/ped4.12439.
Outcomes of Emicizumab in Acquired Hemophilia Patients: A Systematic Review.
Ikbel G, Hela B, Yassine K, Hamida K, Kamel B Clin Appl Thromb Hemost. 2024; 30:10760296241298661.
PMID: 39543979 PMC: 11565686. DOI: 10.1177/10760296241298661.
Freedom From Bleeds With Low-Dose Emicizumab Prophylaxis in Inhibitor-Positive Hemophilia A.
Radhakrishnan N, Pandharipande A, Singh S, Verma S, Baby E, Pandey A J Hematol. 2024; 13(5):186-191.
PMID: 39493600 PMC: 11526584. DOI: 10.14740/jh1346.
Expert Opinions on the Management of Hemophilia A in India: The Role of Emicizumab.
Gupta N, Dutta A, Ahmed B, Ross C, S C, Dolan G Cureus. 2024; 16(4):e58941.
PMID: 38725780 PMC: 11081140. DOI: 10.7759/cureus.58941.
Maneekhiew S, Kovitwanawong N, Raweekul S, Kijkunasathian C, Panuwannakorn M, Uampornvanich P Health Sci Rep. 2024; 7(4):e2003.
PMID: 38567187 PMC: 10985220. DOI: 10.1002/hsr2.2003.